MLN - motilin Gene

Canis lupus familiaris (sub-species: familiaris)

Gene ID: 481748 | Gene type: protein coding

About MLN

mRNA	Protein	Name
NM_001313806.1	NP_001300735.1	motilin precursor

Protein Preferred Names

Protein Names

motilin

Approval

Bioactive Molecules (3)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-10453	Ixazomib		99.85%	Yes
HY-15246	Tovorafenib	Inhibitor	99.89%	Unkown
HY-10452	Ixazomib citrate		99.87%	Yes

Clinical Phase

Bioactive Molecules (10)

Cat. No.	Product Name	Effect	Purity	Phase
HY-70062	Pevonedistat		99.98%	Phase 3
HY-10971	Alisertib		99.84%	Phase 3
HY-10484	Pevonedistat hydrochloride		99.19%	Phase 3
HY-10971A	Alisertib sodium		/	Phase 3
HY-13328	Sapanisertib		99.66%	Phase 2
HY-19414	MLN-4760	Inhibitor	99.93%	Phase 2
HY-12285	Serabelisib	Inhibitor	99.44%	Phase 2
HY-10202	Tandutinib		99.48%	Phase 2
HY-10202A	Tandutinib hydrochloride		99.78%	Phase 2
HY-100487	TAK-243		98.38%	Phase 1

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99781	Plozalizumab	Inhibitor	95.00%	Phase 2
HY-P99662	Indusatumab vedotin		/	Phase 2

Pre-clinical Phase

Bioactive Molecules (16)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-111373	RapaLink-1		99.92%	Unkown
HY-15473	MLN120B	Inhibitor	99.76%	Unkown
HY-10180	MLN8054	Inhibitor	99.54%	Unkown
HY-15155	MLN0905	Inhibitor	99.94%	Unkown
HY-N6746	Citrinin		99.72%	Unkown
HY-123763	MLN3126	Antagonist	98.64%	Unkown
HY-19414A	(R)-MLN-4760	Inhibitor	99.51%	Unkown
HY-15473A	MLN120B dihydrochloride	Inhibitor	99.73%	Unkown
HY-10180A	MLN8054 sodium	Inhibitor	/	Unkown
HY-123143	XR11576	Inhibitor	/	Unkown
HY-156401	BRD9 Degrader-1	Inhibitor	/	Unkown
HY-P6008	Myoregulin		/	Unkown
HY-P6008A	Myoregulin TFA		/	Unkown
HY-RS08498	MLN Human Pre-designed siRNA Set A	Pre-designed Sets	/	Unkown
HY-10202B	Tandutinib sulfate		/	Unkown
HY-W748328	Ixazomib-13C2,15N		/	Unkown

Species	Symbol	Source	ID
Homo sapiens	MLN	NCBI	NCBI:4295
Macaca fascicularis	MLN	NCBI	NCBI:102146298
Mus musculus	MLN	NCBI
Rattus norvegicus	MLN	NCBI	NCBI:100126231

Name
Email *

	Sorry, but the email address you supplied was invalid.